Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiaowei, Shi, Qiyun, Xuhong, Juncheng, Zhang, Yi, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546716/
https://www.ncbi.nlm.nih.gov/pubmed/37789330
http://dx.doi.org/10.1186/s13058-023-01694-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546716/
https://www.ncbi.nlm.nih.gov/pubmed/37789330
http://dx.doi.org/10.1186/s13058-023-01694-5

Ejemplares similares